or Try an Advanced Search...

    Technical Analysis for SCLX - Scilex Holding Company

    Grade Last Price % Change Price Change
    F 0.56 -1.17% -0.01
    SCLX closed down 13.29 percent on Wednesday, November 20, 2024, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical SCLX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -1.17%
    NR7 Range Contraction -1.17%
    Wide Bands Range Expansion -1.17%
    Gapped Down Weakness -1.17%
    Oversold Stochastic Weakness -1.17%
    Lower Bollinger Band Walk Weakness -14.30%
    Inside Day Range Contraction -14.30%
    Wide Bands Range Expansion -14.30%
    Oversold Stochastic Weakness -14.30%
    Lower Bollinger Band Walk Weakness -12.13%
    Older End-of-Day Signals for SCLX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 1% about 3 hours ago
    Up 3% about 4 hours ago
    Up 2% about 4 hours ago
    Up 1% about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SCLX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Scilex Holding Company Description

    Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - General
    Keywords: Pain Organ Systems Pharmaceutical Products Opioids Chronic Pain Pain Management Acute Pain Acute And Chronic Pain Palliative Care Nociception

    Is SCLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 11 Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
    Nov 6 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previo...
    Oct 30 Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock
    Oct 30 Scilex Pharmaceuticals announces end of phase II meeting with FDA for SP-103
    Oct 16 Scilex gains on spinoff plans for pharma subsidiary
    Oct 16 Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of secu...
    Oct 16 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semn...
    Oct 7 Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes
    Oct 7 Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile
    Sep 26 Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
    See more SCLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.63
    52 Week Low 0.5377
    Average Volume 2,194,399
    200-Day Moving Average 1.26
    50-Day Moving Average 0.89
    20-Day Moving Average 0.85
    10-Day Moving Average 0.73
    Average True Range 0.11
    RSI (14) 29.08
    ADX 22.89
    +DI 16.96
    -DI 28.78
    Chandelier Exit (Long, 3 ATRs) 0.81
    Chandelier Exit (Short, 3 ATRs) 0.87
    Upper Bollinger Bands 1.16
    Lower Bollinger Band 0.54
    Percent B (%b) 0.03
    BandWidth 72.08
    MACD Line -0.09
    MACD Signal Line -0.05
    MACD Histogram -0.0355
    Fundamentals Value
    Market Cap 89.15 Million
    Num Shares 158 Million
    EPS -1.16
    Price-to-Earnings (P/E) Ratio -0.49
    Price-to-Sales 5.73
    Price-to-Book 28.85
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.66
    Resistance 3 (R3) 0.67 0.64 0.65
    Resistance 2 (R2) 0.64 0.62 0.64 0.64
    Resistance 1 (R1) 0.60 0.60 0.59 0.60 0.64
    Pivot Point 0.58 0.58 0.57 0.57 0.58
    Support 1 (S1) 0.54 0.55 0.52 0.53 0.49
    Support 2 (S2) 0.51 0.54 0.51 0.49
    Support 3 (S3) 0.47 0.51 0.48
    Support 4 (S4) 0.47